Lyme Disease Diagnostics Market Size Worth USD 2.1 Billion in 2031, to Expand at a 3.8% CAGR Says, Transparency Market Research
14 août 2023 06h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Lyme disease diagnostics market is expected to total US$ 1.56 billion in 2023...
Fecal Immunochemical Diagnostic Test (FIT) Market to Surge with USD 2.1 Billion Expansion by 2031, According to TMR Study
06 juin 2023 08h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 06, 2023 (GLOBE NEWSWIRE) -- The market value of fecal immunochemical diagnostic tests (FITs) is expected to reach US$ 2.1 billion by 2031. Between 2023 and...
Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process
28 mars 2023 08h05 HE
|
Lucira Health Inc.
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access...
Prolocor Announces a Combined $5.2 Million in Funding From Seed Round and NIH SBIR Grant
16 août 2022 09h00 HE
|
Prolocor Inc
PHILADELPHIA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by...
Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test
11 août 2022 07h01 HE
|
Lucira Health Inc.
EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and...
Prolocor to Participate at Biotech Showcase 2022
10 janv. 2022 09h00 HE
|
Prolocor Inc
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Prolocor Inc, a healthcare startup developing an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets, today...
Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways
12 oct. 2021 08h00 HE
|
Scipher Medicine Corporation
ATLANTA and WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Trellis Rx, a leading technology-enabled specialty pharmacy services provider, today announced the integration of PrismRA®, a diagnostic...
Virology Market Valuation to Outstrip $5.27Bn by 2028 Growth Projection at 3.6% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
21 sept. 2021 08h51 HE
|
The Insight Partners
New York, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Virology Market: Key InsightsAccording to our latest study on “Virology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type,...
Scipher Medicine Increases Patient Access for Prismra® by Expanding Intended Use in Autoimmune Patients
29 juil. 2021 09h22 HE
|
Scipher Medicine Corporation
Expanded intended use for the blood test validated in Network-004 study.Now, most rheumatoid arthritis patients can be tested at any point in their clinical journey.Test enables providers to identify...
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
11 févr. 2021 08h00 HE
|
Scipher Medicine Corporation
WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with WellDyne, a...